Payment overview · 2025
General Payments
$229.03
13 reported records · 7 companies
Healthcare provider profile · identity verified
Dustin Markle
Allopathic & Osteopathic Physicians|Family Medicine · CHARLOTTESVILLE, VA · NPI 1245529437
Verified facts
What the public records show
CMS Open Payments records show Dustin Markle received $229.03 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.10 | 38.0% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $34.72 | 15.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.15 | 14.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.47 | 12.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.09 | 7.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.54 | 6.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.96 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.03 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.10 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $34.72 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.45 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $32.15 | 2 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $29.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 98 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
119 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
152 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
98 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 649 | 184 |
| Gabapentin | Gabapentin | 540 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 508 | 145 |
| Omeprazole | Omeprazole | 394 | 113 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 380 | 57 |
| Losartan Potassium | Losartan Potassium | 299 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 289 | 83 |
| Carvedilol | Carvedilol | 287 | 85 |
| Tramadol Hcl | Tramadol Hcl | 282 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 269 | 73 |
| Lisinopril | Lisinopril | 258 | 73 |
| Furosemide | Furosemide | 249 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 222 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 70 |
| Metformin Hcl | Metformin Hcl | 218 | 59 |
| Potassium Chloride | Potassium Chloride | 215 | 62 |
| Famotidine | Famotidine | 211 | 67 |
| Alprazolam | Alprazolam | 204 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 184 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 166 | 49 |
| Clonazepam | Clonazepam | 160 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 46 |
| Ozempic | Semaglutide | 152 | 29 |
| Montelukast Sodium | Montelukast Sodium | 150 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 47 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 148 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 41 |
| Pregabalin | Pregabalin | 140 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 139 | 57 |
| Trazodone Hcl | Trazodone Hcl | 139 | 47 |
| Allopurinol | Allopurinol | 136 | 42 |
| Simvastatin | Simvastatin | 136 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 37 |
| Meloxicam | Meloxicam | 123 | 36 |
| Mounjaro | Tirzepatide | 119 | 20 |
| Sertraline Hcl | Sertraline Hcl | 113 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 105 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 32 |
| Lorazepam | Lorazepam | 100 | 17 |
| Ezetimibe | Ezetimibe | 99 | 28 |
| Eliquis | Apixaban | 98 | 20 |
| Metformin Hcl Er | Metformin Hcl | 97 | 32 |
| Buspirone Hcl | Buspirone Hcl | 95 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 26 |
| Promethazine Hcl | Promethazine Hcl | 94 | 20 |
| Spironolactone | Spironolactone | 93 | 31 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 87 | 25 |
| Donepezil Hcl | Donepezil Hcl | 86 | 23 |
| Bupropion Xl | Bupropion Hcl | 80 | 21 |
| Jardiance | Empagliflozin | 73 | 19 |
| Celecoxib | Celecoxib | 71 | 17 |
| Glimepiride | Glimepiride | 71 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 17 |
| Linzess | Linaclotide | 63 | 12 |
| Ibuprofen | Ibuprofen | 61 | 16 |
| Meclizine Hcl | Meclizine Hcl | 60 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 60 | 14 |
| Baclofen | Baclofen | 59 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 59 | 18 |
| Glipizide | Glipizide | 59 | 17 |
| Ondansetron Odt | Ondansetron | 58 | 30 |
| Estradiol | Estradiol | 55 | 16 |
| Fenofibrate | Fenofibrate | 55 | 13 |
| Diazepam | Diazepam | 54 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 14 |
| Mirtazapine | Mirtazapine | 51 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Levetiracetam | Levetiracetam | 47 | 12 |
| Lovastatin | Lovastatin | 47 | 14 |
| Benazepril Hcl | Benazepril Hcl | 45 | 13 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 44 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | 12 |
| Torsemide | Torsemide | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 15 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Nystatin | Nystatin | 31 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 23 |
| Cephalexin | Cephalexin | 24 | 20 |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Colchicine | Colchicine | 19 | 13 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Zaleplon | Zaleplon | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Irbesartan | Irbesartan | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 14 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Felodipine Er | Felodipine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.03 · 13 records | Lilly USA, LLC | ACCOLADE SR, CAPLYTA, Dexcom G6 Transmitter, ELIQUIS, MOUNJARO, NURTEC ODT, VRAYLAR, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error